Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC
Biomarker testing where appropriate and novel tailored combination therapies targeting multiple pathways simultaneously may address the high unmet need and optimize treatment outcomes in hormone receptor–positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients who develop resistance or have disease recurrence while on endocrine-based therapy (ET), said Professor Sherko Kümmel of the Interdisciplinary Breast Unit Clinics, Essen-Mitte, Germany, who spoke at the 14th Asia-Pacific Breast Cancer Summit (APBCS 2026).
